KDR and neoplasm: This resistance mechanism likely associates with ADM’s roles in promoting angiogenesis and sculpting immunosuppressive microenvironments: ADM activates the VEGFR2 pathway to counteract sorafenib’s inhibitory effects on endothelial cells while simultaneously recruiting MDSCs to diminish drug-mediated tumor cell cytotoxicity.